mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer

This study is a prospective, single-arm, multicenter, phase Ib/II clinical trial that treats previously untreated patients with locally advanced or metastatic pancreatic cancer using mFOLFIRINOX in combination with anlotinib and sintilimab. The purpose of this trial is to evaluate the efficacy and safety of this treatment regimen and to preliminarily explore the correlation between biomarkers and treatment outcomes.

Trial Details

NCT ID
NCT06761027
Phase
PHASE1 / PHASE2
Sponsor
Fujian Provincial Hospital
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Anlotinib combined with Sintilimab
Locations (sample)
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Zhangzhou, Fujian, China|24.51333,117.65556

Key Eligibility Criteria

  • Fully understand this study and voluntarily sign the informed consent form;
  • Age between 18 and 75 years inclusive, with no gender restrictions;
  • Patients with locally advanced or metastatic pancreatic cancer diagnosed by histology or cytology;
  • No prior anti-cancer treatment;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →